If you are an Aetna member and received a letter regarding contract negotiations with NewYork-Presbyterian, you may find out the latest information here.

Bishoy M. Faltas, M.D.

Hematology/Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

My philosophy is simple: the patient comes first. As part of the Genitourinary Oncology Program at Weill Cornell Medicine, I am committed to delivering the best care to my patients. Our world-class multidisciplinary team ensures that we treat the patient as a whole, not just the cancer. I am driven by the desire to improve therapy of urological malignancies by identifying the genetic “Achilles heel” of each patient’s cancer. Through my research, I am committed to developing “precision medicine” approaches and conducting clinical trials for treatment of bladder cancer and other genitourinary malignancies. 

Biographical Info

Dr. Bishoy Morris Faltas is an Assistant Professor of Medicine at Weill Cornell Medicine and an Assistant Attending in the Genitourinary Oncology Program in the Division of Hematology & Medical Oncology. 

Dr. Faltas completed his Hematology and Medical Oncology Fellowship at Weill Cornell Medicine, as well as additional training through a research fellowship in the laboratory of Dr. Mark A. Rubin. During this time, he led studies of the clonal evolution and the neoantigenic structure of platinum-resistant bladder cancer. As a physician-scientist, Dr. Faltas conducts research focusing on understanding the molecular profiles of metastatic platinum-resistant urothelial bladder cancer. His research focus is on the mechanisms of mutagenesis and drug-resistance in bladder carcinoma, as well as immunogenomic studies of urological malignancies. By understanding the molecular changes that occur as urothelial cancer evolves under the effect of chemotherapy and metastatic spread, Dr. Faltas aims to identify potential drug targets for translation into therapeutic clinical trials. He is an active member of the The Caryl and Israel Englander Institute for Precision Medicine focusing on the application of genomic approaches to clinical trials by tailoring treatment based on the unique molecular profile of each patient’s cancer. 

Dr. Faltas is the recipient of several research awards, including the Scott-Wadler Fellow Research award and the Weill Department of Medicine Fellow Award in Research. He has also received the NIH/NCATS CTSC KL2 Scholar grant, the American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Award and the Department of Defense Career Development Award.

Dr. Faltas has published several articles in peer-reviewed journals such as the Nature Genetics, New England Journal of Medicine, JAMA Oncology, Journal of Clinical Oncology. Additionally, he is a reviewer for several journals including Nature Communications, American Journal of Medicine, Science Translational Medicine, and Nature Scientific Reports. Dr. Faltas is a member of the editorial board of the ASCO Post. He also served as an Associate Scientific Advisor for the journal Science Translational Medicine.

Honors and Awards

American Association for Cancer Research(AACR) NextGen Star (2017)

Finalist, best research presentation, Immuno-oncology Young Investigators’ forum (2016)

American Society of Clinical Oncology (ASCO) Merit Award to present at the 2016 ASCO annual Genitourinary symposium (2016)

2014-2015 Scott Wadler Memorial Fellow Clinical Research Award (2015)

1st place in Department of Medicine Fellows Research Award competition, Weill Cornell Medical College (2015)

American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award (2015)

American Society of Clinical Oncology (ASCO) Merit Award to present at the 2015 ASCO annual meeting (2015)

American Society of Clinical Oncology (ASCO) Merit Award to present at the 2015 ASCO annual Genitourinary symposium (2015)

2013-2014 Scott Wadler Memorial Fellow Clinical Research Award (2014)

Award to attend the Annual AACR Workshop: Molecular Biology in Clinical Oncology (2014)

Award to attend the Cancer Education Consortium Molecular and Translational Oncology Workshop (2014)

Scholarship to attend ASCO-AACR Methods in Clinical Oncology Workshop (2013)

American Medical Association (AMA) Policy Promotion Grant (2009)

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
Bladder Cancer
Cancer of Ureter
Urethral Cancer
Prostate Cancer
Kidney Cancer
Immunotherapy
Genomics
Languages
English
Education 
  • M.B.,B.S.
    College of Medicine Assiut (Egypt)
    2005
Appointments 
  • Assistant Attending Physician
    NewYork-Presbyterian Hospital
  • Assistant Professor of Medicine
    Weill Cornell Medical College, Cornell University
  • Assistant Professor of Cell and Developmental Biology
    Weill Cornell Medical College, Cornell University
  • Gellert Family-John P. Leonard, M.D. Research Scholar
    Weill Cornell Medical College, Cornell University
Videos

Bishoy Faltas, MD

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
Astrin Biosciences, Inc.
BostonGene
Professional Services: 
UroToday
Advisory/Scientific Board Member: 
Immunomedics, Inc.
Seattle Genetics, Inc.
Springer Publishing Company
Other Interest: 
BostonGene
Gilead Sciences, Inc.
Guardant Health, Inc.
Merck & Co., Inc.
Natera, Inc.